Extensive exploration into the interaction between programmed cell death protein-1, (PD-1) and programmed death-ligand 1 (PD-L1) within the tumour microenvironment has led to significant breakthroughs in the treatment of malignancies associated with these immune checkpoint proteins [1,2]. The gene discussed is PDCD1; the disease is neoplasm.